Officials from CardiAI and Carleton University. Credit: CNW Group/CardiAI.

Biotechnology company CardiAI has announced a partnership with the Faculty of Engineering and Design at Carleton University in Canada to advance point-of-care medical diagnostics.

The collaboration is set to advance medical diagnostics by developing EG-FET biosensor technology, which will be used for detecting critical biomarkers in saliva and whole blood.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This technology is expected to deliver highly sensitive and specific results, improving the accuracy of medical diagnostics.

The focus is on detecting NT-proBNP and cardiac troponin biomarkers, with the potential to expand to other health conditions.

The collaboration aims to have a worldwide impact by enhancing the accessibility of medical tests and contributing to the health of individuals globally.

Carleton Organic Sensors and Devices Laboratory head and Carleton Department of Electronics associate professor Dr Ravi Prakash said: “This collaboration exemplifies the power of interdisciplinary partnerships in driving scientific progress.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our department is excited to contribute to the development of cutting-edge biosensor technology that has the potential to redefine point-of-care diagnostics.

“By combining our research strengths, we aim to make a lasting impact on healthcare accessibility and usher in a new era of medical innovation.”

The parties will also integrate the biosensor technology with BioAro’s artificial intelligence-powered Telemedicine Platform and Electronic Medical Records system, BioEMR, to streamline healthcare services, enabling better patient management and diagnostic reporting.

CardiAI cardiologist and CEO Dr Anmol Kapoor said: “Together, we are committed to advancing technology that not only addresses current healthcare challenges but also opens new doors for innovation and improved patient outcomes.”

In 2022, CardiAI introduced BPAro, a new 24-hour ambulatory blood pressure monitoring system.